Celldex Therapeutics, Inc. - 8-K Filing

Celldex Therapeutics reports Q3 2026 net loss of $75.6 million and announces Phase 3 barzolvolimab success in CSU. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 5, 2026, 21:01 UTC

Tickers: $CLDX

Read the full article at SEC EDGAR

More Regulatory news

Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC
Beyond Air, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:17 UTC
Carter Bankshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:12 UTC
Marvell Technology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
VISHAY INTERTECHNOLOGY INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
LATTICE SEMICONDUCTOR CORP - 4 Filing SEC EDGAR · November 12, 2026, 14:10 UTC